• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    MediPal Holdings (TSE:7459) Stock Looks Reasonable Against Future Cash Flow

    Simply Wall St·09/20/2026 01:28:52
    Listen to the news

    MediPal Holdings has delivered steady share price gains in recent years, which puts a spotlight on whether the current valuation is properly grounded in its future cash flows. With the market now watching both its core healthcare distribution business and newer initiatives, the question is how much of that story is already reflected in today's price.

    • Over the past 5 years, MediPal Holdings has returned 50.1%, which raises the issue of how much long term cash generation the current share price is implying.
    • The recent start of a global Phase I/II trial for JR-446, where MediPal holds commercialization rights outside Japan, may support expectations for future cash inflows if the therapy progresses successfully and eventually reaches the market.
    • Prefer to judge MediPal Holdings on earnings? See what MediPal Holdings's 12.8x P/E says about the price.

    The issue now is whether MediPal Holdings' current share price is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) based intrinsic value estimate.

    If you want to test whether MediPal Holdings' cash flow story and DCF lens stack up against a wider field, line it up beside companies in the 17 high quality undervalued stocks

    Does MediPal Holdings Look Undervalued on Cash Flow?

    The Discounted Cash Flow (DCF) model here looks at the cash MediPal Holdings can return to shareholders over time and then discounts it back to today. Latest twelve month free cash flow sits at about ¥32.3b, with the model assuming that future cash generation grows in the near term and then tapers off into lower projected figures in the 2030s, which is typical for a mature distributor with some higher risk pipelines attached.

    These cash flow assumptions point to an estimated intrinsic value that the DCF suggests is meaningfully above the current share price of ¥2,906.50. The recent start of the global Phase I/II trial for JR-446 for MPS IIIB, where MediPal holds commercialization rights outside Japan, adds a long dated optional component to those projections. This helps explain why the model supports more value than the equity market is currently willing to pay. Find out what MediPal Holdings could be worth using our Discounted Cash Flow (DCF) estimate.

    The MediPal Holdings Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where that valuation question for MediPal Holdings' shares leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or materially less than the current price. Each one links its number to a specific view on how MediPal Holdings' expansion prospects, profitability and risks might evolve, giving you a reference point you can revisit as new information comes through on the Community page.

    A written narrative on MediPal Holdings is useful now because it pins down a clear, number driven view that investors can revisit as the DCF assumptions meet reality. With the first patient dosed in the global Phase I/II trial of JR-446, it also gives you a structured way to track whether that potential therapy ultimately supports the cash flow profile implied in today's share price.

    Share your own Narrative for MediPal Holdings and set out the assumptions behind your valuation.

    MediPal Holdings' value still hinges on who is steering it

    Before you stop at the numbers, it is worth asking who is actually making the key calls at MediPal Holdings and what kind of pay package nudges their decisions over time. See who runs MediPal Holdings and how they are paid.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.